SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : TITAN PHARMACEUTICAL (TTP) -- Ignore unavailable to you. Want to Upgrade?

To: biofreak who wrote (284)6/16/2004 12:53:54 AM
From: Miljenko Zuanic  Read Replies (1) | Respond to of 362
 
Interest in HDI is growing, no question here.

Is butyric acid derivative the best option? Pivanex is not without toxicity (toxicity of the butyric acid) and therapeutic window may not be sufficient to deliver needed rise in efficacy. Anyway, by year-end we will know does Pivanex work and can compete in NSCLC market.

Glad to see that Spheramine is alive.

Miljenko


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News